secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-05-27T11:05:55+00:00
Accession:  0001493152-26-025324
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix publishes Phase 1 data for TNX-1500; shows TDAR blockade, favorable safety
--------------------------------------------------------------------------------

- TNX-1500 Phase 1 data in Journal of Clinical Immunology; blocked primary TDAR at all doses (3,10,30 mg/kg).
- Secondary TDAR blocked at 10 and 30 mg/kg; peak secondary reduced ~70% vs placebo at 3 mg/kg.
- No serious adverse events; mild aphthous ulcers in 3 participants; half-life supports monthly IV dosing.
- Phase 2 investigator-initiated kidney transplant study at MGH expected to start 2H 2026 pending FDA IND clearance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226025324/0001493152-26-025324-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226025324/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-025324

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer